Inclisiran keeps on giving
Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.
Covid-19 oils the wheels of business development
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
Astrazeneca throws Silence an $80m lifeline
Silence has received an important validation, but making progress could be tough.
Speedy nod sets Alnylam up for its second launch
Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Medicines Company goes on the hunt for heartening Orion data
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Pfizer shoots for a high price with tafamidis
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
EASL 2019 – Alnylam lays out givosiran's benefit
Full data from Alnylam's pivotal givosiran programme show a big impact for severe patients, though a case still needs to be made for a broader population.
